Imetelstat plus ruxolitinib for myelofibrosis
phase 2drug program · high · Wed May 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify a recommended Part 2 dose of imetelstat sodium in combination with ruxolitinib in myelofibrosis and evaluate safety plus preliminary clinical activity at that dose.
Part 1 dose-finding followed by Part 2 evaluation of imetelstat sodium combined with ruxolitinib.
ClinicalTrials.gov record for the combination myelofibrosis study was published on 2022-05-04.
Imetelstat for relapsed or refractory myelofibrosis after JAK inhibitor treatment
phase 3drug program · high · Mon Apr 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate overall survival and clinical benefit of imetelstat compared with best available therapy in participants with intermediate-2 or high-risk myelofibrosis who are relapsed or refractory to Janus kinase inhibitor treatment.
Randomized clinical trial comparing imetelstat with best available therapy in JAK-inhibitor relapsed/refractory myelofibrosis.
ClinicalTrials.gov record for imetelstat versus best available therapy in intermediate-2 or high-risk myelofibrosis was published on 2021-04-12.
Imetelstat for relapsed/refractory intermediate-2 or high-risk myelofibrosis after JAK inhibitor treatment
phase 3drug program · high · Mon Apr 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate overall survival for participants with intermediate-2 or high-risk myelofibrosis who are relapsed or refractory to Janus kinase inhibitor treatment.
Randomized clinical trial comparing imetelstat to best available therapy.
ClinicalTrials.gov record for the comparative myelofibrosis study was published on 2021-04-12.
Imetelstat for lower-risk myelodysplastic syndrome
approveddrug program · high · Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis-stimulating agent treatment, with efficacy measured by red blood cell transfusion independence and continued assessment of long-term safety, overall survival, and progression to acute myeloid leukemia.
Clinical development of imetelstat sodium, a telomerase-inhibition drug, in a Phase 2/Phase 3 trial versus placebo with a QTc substudy and extension phase.
Geron states it has a medicine approved for use in the United States; the supplied clinical record describes the Phase 2/Phase 3 MDS study and extension phase.
Imetelstat dose-ranging program for relapsed or refractory myelofibrosis
phase 2drug program · high · Fri Aug 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate efficacy and safety of two dose regimens of imetelstat in participants with intermediate-2 or high-risk myelofibrosis relapsed after or refractory to Janus kinase inhibitor treatment, including overall survival as a key secondary endpoint.
Clinical study comparing two imetelstat dose regimens in JAK-inhibitor relapsed/refractory myelofibrosis.
ClinicalTrials.gov record for the two-dose imetelstat myelofibrosis study was published on 2015-08-28.
Imetelstat dose-regimen study for intermediate-2 or high-risk myelofibrosis after JAK inhibitor treatment
phase 2drug program · high · Fri Aug 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate efficacy and safety of two imetelstat dose regimens in participants with intermediate-2 or high-risk myelofibrosis whose disease relapsed after or was refractory to JAK inhibitor treatment, with overall survival as a key secondary endpoint.
Clinical study comparing two dose regimens of imetelstat.
ClinicalTrials.gov record for the two-dose myelofibrosis study was published on 2015-08-28.
Imetelstat for primary or secondary myelofibrosis and other myeloid malignancies
phase 2drug program · high · Mon Oct 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Study how well imetelstat sodium works in participants with primary or secondary myelofibrosis and other myeloid malignancies.
Pilot clinical trial of imetelstat sodium intended to block enzymes needed for cancer cell growth.
ClinicalTrials.gov record for the pilot myelofibrosis and myeloid malignancy study was published on 2012-10-29.
Imetelstat for essential thrombocythemia or polycythemia vera
phase 2drug program · high · Wed Dec 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate single-agent imetelstat in patients with essential thrombocythemia or polycythemia vera who failed, were intolerant to, or refused standard therapy.
Open-label Phase II clinical study of single-agent imetelstat.
ClinicalTrials.gov record for the ET/PV open-label Phase II study was published on 2010-12-01.
Imetelstat for previously treated multiple myeloma
phase 2drug program · high · Mon Nov 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Determine the rate of improvement in response among previously treated multiple myeloma patients with detectable but non-progressing disease who received imetelstat alone or with lenalidomide maintenance therapy.
Open-label Phase II study of imetelstat alone or in combination with lenalidomide maintenance therapy.
ClinicalTrials.gov record for the multiple myeloma Phase II study was published on 2010-11-01.
Telomerase inhibition research platform
exploratoryplatform · medium
Develop innovative medicines for myeloid hematologic malignancies and blood cancers using telomerase inhibition as the primary approach.
Research and development program focused on telomerase inhibition, pipeline development, and clinical trials.
Geron site analysis identifies telomerase inhibition as the primary approach and points to pipeline, telomerase inhibition, and clinical trials pages.
